RecruitingPhase 2NCT07347249
Rare condition
Congenital factor VII deficiency
3
studies recruiting now
as of 7 Sept 2026
15
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
12 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT06349473
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RecruitingPhase 1 / Phase 2NCT07644832
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
Showing the 3 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Congenital factor VII deficiency studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Congenital factor VII deficiency study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Congenital factor VII deficiency
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (F7).
Treatments being studied
1 approved treatment, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Eptacog Alfa (Activated) (Novoseven)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).